论文部分内容阅读
目的探究分析三氧化二砷(ATO)联合改良氟达拉滨、阿糖胞苷、粒系集落刺激因子(FLAG)方案治疗复发难治急性髓性白血病的临床疗效。方法选取我院2009年5月～2012年5月收治的复发难治急性髓性白血病患者50例并随机分组,每组25例,对照组采用常规ATO联合大剂量阿糖胞苷方案治疗,试验组采用ATO联合改良FLAG方案治疗。记录并比较两组治疗三个疗程后临床疗效情况。结果试验组总有效率分别为92.0%,较对照组(64%)明显偏高,P<0.05,具有统计学意义。结论 ATO联合改良FLAG方案治疗复发难治急性髓性白血病临床疗效显著,有一定推广价值。
Objective To investigate the clinical efficacy of combination of arsenic trioxide (ATO) and modified fludarabine, cytarabine and granulocyte colony stimulating factor (FLAG) in the treatment of refractory acute myeloid leukemia. Methods Fifty patients with refractory acute myeloid leukemia who were treated in our hospital from May 2009 to May 2012 were randomly divided into two groups, 25 cases in each group. The control group was treated with conventional ATO combined with high-dose cytarabine. Group using ATO combined with improved FLAG regimen. Record and compare the clinical efficacy of the two groups after three courses of treatment. Results The total effective rate of the experimental group was 92.0%, which was significantly higher than that of the control group (64%), P <0.05, with statistical significance. Conclusion ATO combined with modified FLAG regimen in treatment of relapsed and refractory acute myeloid leukemia has obvious curative effect and has certain promotion value.